In the beginning of 2006 GlaxoSmithKline Ltd, Bulgaria, (GSK) notified the Commission on Protection of Competition (CPC) about an exclusive distribution agreement (Agreement) entered into between GSK and Agroengineering-90 Ltd (Agroengineering) on 21 December 2005. Subject of the agreement are life-saving medicinal products included in the scope of a public procurement procedure before the Bulgarian Ministry of Health (MH). GSK alleged that the Agreement did not infringe the national provision similar to Art. 101 (1) TFEU due to insignificant effect on the market or in the event that it was found to infringe this provision, it should be exempted on the basis of the national provision similar to Art. 101 (3) TFEU. According to the Agreement GSK as a manufacturer of the medicines and
The Bulgarian Competition Authority grants an individual exemption of an exclusive distribution agreement (GlaxoSmithKline)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.